Skip to main content
Back
TRUMY logo

Terumo Corporation

Data quality: 100%
TRUMY
OTC Healthcare Medical - Instruments & Supplies
$13.26
▲ $0.71 (5.66%)
Mkt Cap: 19.56B
Also listed as TRUMF OTC
Day Range
$13.10 $13.50
52-Week Range
$12.15 $20.12
Volume
53,182
50D / 200D Avg
$13.27 / $15.85
Prev Close
$12.55

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 0.2 0.4
P/B 0.0 2.9
ROE % 8.7 3.8
Net Margin % 11.3 3.9
Rev Growth 5Y % 14.0 10.0
D/E 0.1 0.2

Key Takeaways

Revenue grew 13.98% annually over 5 years — strong growth
Debt/Equity of 0.13 — conservative balance sheet
Generating 128.44B in free cash flow
P/E of 0.17 — trading at a low valuation
Cash machine — converts 109.80% of earnings into free cash flow
Capital efficient — spends only 7.95% of revenue on capex

Growth

Revenue Growth (5Y)
13.98%
Revenue (1Y)12.40%
Earnings (1Y)9.97%
FCF Growth (3Y)68.27%

Quality

Return on Equity
8.68%
ROIC7.66%
Net Margin11.29%
Op. Margin15.22%

Safety

Debt / Equity
0.13
Current Ratio3.00
Interest Coverage25.24

Valuation

P/E Ratio
0.17
P/B Ratio0.01
EV/EBITDA-0.17
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12.40% Revenue Growth (3Y) 12.40%
Earnings Growth (1Y) 9.97% Earnings Growth (3Y) 14.44%
Revenue Growth (5Y) 13.98% Earnings Growth (5Y) 10.92%
Profitability
Revenue (TTM) 1.04T Net Income (TTM) 116.98B
ROE 8.68% ROA 6.40%
Gross Margin 54.11% Operating Margin 15.22%
Net Margin 11.29% Free Cash Flow (TTM) 128.44B
ROIC 7.66% FCF Growth (3Y) 68.27%
Safety
Debt / Equity 0.13 Current Ratio 3.00
Interest Coverage 25.24 Dividend Yield 0.01%
Valuation
P/E Ratio 0.17 P/B Ratio 0.01
P/S Ratio 0.02 PEG Ratio 3.39
EV/EBITDA -0.17 Dividend Yield 0.01%
Market Cap 19.56B Enterprise Value -27.47B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.04T 921.86B 820.21B 703.30B 613.84B
Net Income 116.98B 106.37B 89.33B 88.81B 77.27B
EPS (Diluted) 78.99 71.47 59.48 58.69 51.05
Gross Profit 560.67B 479.18B 417.37B 369.34B 326.62B
Operating Income 157.67B 140.10B 117.33B 115.96B 98.39B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.83T 1.83T 1.60T 1.47T 1.35T
Total Liabilities 459.86B 504.31B 491.16B 461.38B 494.53B
Shareholders' Equity 1.37T 1.33T 1.11T 1.01T 856.66B
Total Debt 174.84B 268.55B 231.94B 259.01B 293.08B
Cash & Equivalents 221.87B 204.88B 187.32B 205.25B 200.77B
Current Assets 723.50B 722.12B 611.40B 558.71B 523.97B
Current Liabilities 240.97B 379.15B 218.00B 177.72B 211.37B

Strategy Scores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#350 of 1024
52
Custom Deep Value Investing (Seth Klarman)
#273 of 820
51
Growth Price/Sales Ratio Focus (Ken Fisher)
#518 of 616
14
Value Defensive Investing (Benjamin Graham)
#484 of 708
19

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026